Criticism of Teva’s US operation for discontinuing supplies of the vincristine chemotherapy agent is wide of the mark, the Israeli group insists. Publications including the New York Times and Forbes have in recent days highlighted increasing supply shortages of the injectable drug, which is widely used in US hospitals to treat pediatric cancers such as leukemias and lymphomas.
Teva and Pfizer’s Hospira currently hold the only approved abbreviated new drug applications (ANDAs) for vincristine sulfate 1mg/ml pre-filled...